AbbVie Inc (NYSE:ABBV) announced a quarterly dividend on Friday, October 27th, Zacks reports. Stockholders of record on Friday, January 12th will be given a dividend of 0.71 per share on Thursday, February 15th. This represents a $2.84 annualized dividend and a dividend yield of 2.83%. The ex-dividend date is Thursday, January 11th. This is an increase from AbbVie’s previous quarterly dividend of $0.64.
AbbVie has increased its dividend payment by an average of 15.5% annually over the last three years and has raised its dividend every year for the last 45 years. AbbVie has a payout ratio of 51.2% indicating that its dividend is sufficiently covered by earnings. Analysts expect AbbVie to earn $6.56 per share next year, which means the company should continue to be able to cover its $2.84 annual dividend with an expected future payout ratio of 43.3%.
Shares of AbbVie (NYSE:ABBV) opened at $100.24 on Wednesday. The stock has a market capitalization of $159,790.00, a P/E ratio of 24.33, a PEG ratio of 1.20 and a beta of 1.53. AbbVie has a one year low of $59.27 and a one year high of $101.28. The company has a quick ratio of 1.32, a current ratio of 1.45 and a debt-to-equity ratio of 5.08.
A number of equities research analysts recently issued reports on ABBV shares. Leerink Swann reissued a “market perform” rating on shares of AbbVie in a research note on Tuesday, September 12th. SunTrust Banks reissued a “buy” rating and set a $95.00 price target on shares of AbbVie in a research note on Wednesday, September 13th. Piper Jaffray Companies reissued a “buy” rating and set a $100.00 price target on shares of AbbVie in a research note on Friday, September 15th. Jefferies Group reissued a “buy” rating and set a $107.00 price target (up from $94.00) on shares of AbbVie in a research note on Friday, September 15th. Finally, UBS Group lowered AbbVie from a “buy” rating to a “neutral” rating and raised their price target for the stock from $79.00 to $92.00 in a research note on Monday, September 25th. Seven analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $100.94.
In other AbbVie news, insider Henry O. Gosebruch sold 18,300 shares of the firm’s stock in a transaction on Monday, October 30th. The stock was sold at an average price of $90.55, for a total transaction of $1,657,065.00. Following the transaction, the insider now directly owns 81,287 shares in the company, valued at approximately $7,360,537.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Timothy J. Richmond sold 87,040 shares of the firm’s stock in a transaction on Monday, December 18th. The stock was sold at an average price of $98.45, for a total value of $8,569,088.00. Following the transaction, the senior vice president now owns 113,118 shares in the company, valued at $11,136,467.10. The disclosure for this sale can be found here. Insiders have sold a total of 494,676 shares of company stock worth $47,237,938 over the last 90 days. 0.23% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Los Angeles Capital Management & Equity Research Inc. increased its holdings in shares of AbbVie by 24.5% in the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 740,392 shares of the company’s stock valued at $53,686,000 after acquiring an additional 145,691 shares during the period. Spectrum Management Group Inc. increased its holdings in shares of AbbVie by 11.5% in the 2nd quarter. Spectrum Management Group Inc. now owns 28,100 shares of the company’s stock valued at $2,038,000 after acquiring an additional 2,892 shares during the period. AGF Investments America Inc. increased its holdings in shares of AbbVie by 3.6% in the 2nd quarter. AGF Investments America Inc. now owns 29,064 shares of the company’s stock valued at $2,107,000 after acquiring an additional 1,017 shares during the period. Ffcm LLC increased its holdings in shares of AbbVie by 167.2% in the 2nd quarter. Ffcm LLC now owns 1,539 shares of the company’s stock valued at $111,000 after acquiring an additional 963 shares during the period. Finally, Fiduciary Trust Co. increased its holdings in shares of AbbVie by 3.2% in the 2nd quarter. Fiduciary Trust Co. now owns 321,953 shares of the company’s stock valued at $23,345,000 after acquiring an additional 10,113 shares during the period. Institutional investors own 69.18% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.com-unik.info/2018/01/10/abbvie-inc-abbv-declares-dividend-increase-0-71-per-share.html.
AbbVie Company Profile
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.